Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Illumina

Thumbnail
January 14, 2021

Medtechs rake in the venture cash

In terms of private investments, 2020 was the year of the liquid biopsy.

Thumbnail
October 28, 2020

Corporate investing plays an ever bigger role in medtech

The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.

Article image
Vantage logo
October 05, 2020

Bridgebio U-turn shows how money can be made twice over

The company becomes the third in two months to buy back a division it had spun out just a few years earlier.

Article image
Vantage logo
September 25, 2020

Exact gatecrashes the liquid biopsy party

Preliminary data on its pan-cancer blood test appear surprisingly competitive.

Article image
Vantage logo
September 21, 2020

Illumina sees the light – or thinks it does

The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.

Article image
Vantage logo
June 15, 2020

Illumina launches first Covid-19 test to include genetic sequencing

Article image
Vantage logo
March 03, 2020

Thermo Fisher buys Qiagen after all

Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.

Article image
Vantage logo
December 18, 2019

Antitrust watchdog plunges Illumina’s megamerger into darkness

Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.

Article image
Vantage logo
October 25, 2019

Illumina-Pacbio deal hits another snag

Article image
Vantage logo
October 08, 2019

Storm-tossed Qiagen plots a course to higher growth

A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.

Article image
Vantage logo
May 01, 2019

Sequencing groups prompt US pricing reversal's reversal

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.